University of South Florida to Join National Study of HIV Prevention Pill in Young Men
January 2, 2013
The youth trial of Truvada, a drug which received US Food and Drug Administration approval as an HIV preventative drug, will involve 14 communities from Tampa, Fla. to San Francisco. These new trials are in response to the realization that earlier trials of Truvada's effectiveness and safety did not include enough younger men who have sex with men (MSM), a fact made even more noteworthy since a recent CDC report showed that infections have increased 22 percent among 13-24-year-old MSM and young black males are particularly affected.
University of South Florida (USF) researchers are joining the national study to learn how well the daily pill may protect this high-risk population. This month, USF will begin recruiting 25 participants at its new Ybor Youth Clinic, which serves at-risk youth. Dr. Diane Straub, chief of USF's Division of Adolescent Medicine, will be the principal local investigator for the trial. The study, called Project PrEPare (which stands for Pre-Exposure Prophylaxis), will examine the use of Truvada in a broad HIV-prevention strategy. Participants will also receive free condoms, safe-sex counseling, and monthlyView Full Article
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)